Eisai to acquire Morphotek
Upon completion of the transaction, which is expected to close sometime during Eisai’s first fiscal quarter of 2007, Morphotek will become part of Eisai’s growing global discovery and
The US Food and Drug Administration (FDA) has granted accelerated approval to Bristol Myers Squibb’s (BMS) Zenbexus (iberdomide), along with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd), to treat adult multiple myeloma (MM) patients.